Merck, known as MSD outside of the United States and Canada, and Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for a total transaction value of approximately $10 billion. Through this acquisition Merck will add Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmona...